<DOC>
	<DOCNO>NCT01897844</DOCNO>
	<brief_summary>The purpose study assess safety , tolerability , pharmacokinetics ( PK ) pharmacodynamics ( PD ) extend dose regimen ITF2984 : part A , design double-blind , placebo-controlled , randomize , test extend dose regimen , i.e . 14 consecutive dosing day higher dos , i.e . 6000 mcg/day part B , open label , continuous subcutaneous infusion 7 day test ascend dos ITF2984 9000 mcg/day ITF2984 .</brief_summary>
	<brief_title>A Two Part Phase 1 , Repeated Doses Continuous Infusion Study With ITF2984 Healthy Volunteers</brief_title>
	<detailed_description>This two part Phase I repeat incremental dos study male healthy volunteer . The study conduct two part . A total 36 subject plan enrol Part A 36 subject Part B . Part A performed accord double blind , randomize , placebo control design include three sequential dose group repeat dos . Each group enrol 12 subject ITF2984 placebo ( ratio 9 active : 3 placebo ) receive ITF2984 s.c. placebo twice daily 14 day . For three group last dose plan first dose Day 14 . The study start Group 1 2000mcg s.c . b.i.d. , Group 2 receive 3000mcg b.i.d . interim review safety PK data 2000mcg dose level . Group 3 receive 100mcg s.c. gather data complete PK/PD profile ITF2984 . Subjects screen 28 day dose ITF2984/placebo take place Days 1-14 . For Groups , day -1 day 13 subject receive exogenous test administration ( GHRH , Arginin TRH ) 30 minute first morning administration ITF2984/placebo . Part B open label , plan six sequential dose group 6 subject . In group subject receive ITF2984 continuous subcutaneous infusion 7 consecutive day . The dose escalate , start dose 900 mcg , maximum three fold cautiously , deem necessary . The decision test high dose level base review safety PK data previous dose level ( ) . After 28 day screen period , subject admit clinical unit even day -2 . ITF2984 continuous infusion plan day 1 day 8 morning . On day -1 ( day prior start infusion ) subject receive exogenous/challenge test administration ( GH-RH+Arginina TRH ) . On day 7 challenge test repeat .</detailed_description>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Healthy male Aged 18 55 y.o. , inclusive , time signing informed consent Body Mass Index ( BMI ) 18 25 kg/m2 , inclusive Must willing able communicate participate whole study An understanding , ability willingness fully comply study procedure restriction . Ability provide write , personally sign date informed consent participate study complete studyrelated procedure . Subject must willing comply applicable contraceptive requirement protocol Satisfactory medical assessment clinically significant relevant abnormality current medical condition , physical examination , vital sign , ECG laboratory evaluation assess Investigator Current recurrent disease could affect action , absorption disposition investigational medicinal product , could affect clinical laboratory assessment . Current relevant previous history physical psychiatric illness may require treatment make subject unlikely fully complete study , condition present undue risk IMP study procedure . History presence moment screen visit gallstone . Significant illness , judge Investigator , within 2 week first dose IMP . Use prescription nonprescription drug ( 2 g per day paracetamol ) , include vitamin , herbal dietary supplement within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator Medical Monitor medication interfere study procedure compromise subject safety . Known suspected intolerance hypersensitivity IMP , closely related compound state ingredient . History regular alcohol consumption within 6 month study A positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome ) . A positive test HIV antibody . Current use tobacco nicotine containing product form . Ex user must report stop use tobacco least 90 day prior receive first dose investigational medicinal product . A breath carbon monoxide read great 10 ppm screening . Any condition result whole blood loss great 500 mL within 90 day period study participation . The subject participate clinical trial receive investigational product within 6 month prior first dose day current study ( rescreening subject receive study drug study allow ) . Clinically significant abnormal biochemistry , haematology urinalysis judge Investigator . History sensitivity study medication , component thereof history drug allergy , opinion investigator Medical Monitor , contraindicate participation . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitated Subjects fail satisfy Investigator fitness participate study reason .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>volunteer</keyword>
</DOC>